Business Description
Edgewise Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28036F1057
Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.13 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -40.2 | |||||
| 3-Year EPS without NRI Growth Rate | -38.2 | |||||
| 3-Year FCF Growth Rate | -33.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.71 | |||||
| 9-Day RSI | 52.79 | |||||
| 14-Day RSI | 55.87 | |||||
| 6-1 Month Momentum % | -1.24 | |||||
| 12-1 Month Momentum % | 52.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 26.22 | |||||
| Quick Ratio | 26.22 | |||||
| Cash Ratio | 25.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -24.56 | |||||
| ROA % | -23.39 | |||||
| ROIC % | -789.94 | |||||
| ROC (Joel Greenblatt) % | -1128.62 | |||||
| ROCE % | -26.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.87 | |||||
| Price-to-Tangible-Book | 1.87 | |||||
| EV-to-EBIT | -3.53 | |||||
| EV-to-EBITDA | -3.56 | |||||
| EV-to-FCF | -4.02 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Price-to-Net-Cash | 1.98 | |||||
| Earnings Yield (Greenblatt) % | -28.33 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EWTX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Edgewise Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.32 | ||
| Beta | 0 | ||
| Volatility % | 60.15 | ||
| 14-Day RSI | 55.87 | ||
| 14-Day ATR ($) | 0.758993 | ||
| 20-Day SMA ($) | 9.64525 | ||
| 12-1 Month Momentum % | 52.71 | ||
| 52-Week Range ($) | 5.53 - 14.33 | ||
| Shares Outstanding (Mil) | 63.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edgewise Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edgewise Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Edgewise Therapeutics Inc Frequently Asked Questions
What is Edgewise Therapeutics Inc(EWTX)'s stock price today?
The current price of EWTX is $9.70. The 52 week high of EWTX is $14.33 and 52 week low is $5.53.
When is next earnings date of Edgewise Therapeutics Inc(EWTX)?
The next earnings date of Edgewise Therapeutics Inc(EWTX) is 2023-08-04 Est..
Does Edgewise Therapeutics Inc(EWTX) pay dividends? If so, how much?
Edgewise Therapeutics Inc(EWTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers